ArticleMolecules (Basel, Switzerland)2014
Studies on cytotoxic constituents from the leaves of Elaeagnus oldhamii Maxim. in non-small cell lung cancer A549 cells.
Article in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Profiling and Bioactivity of Polyphenols from the Omani Medicinal PlantMolecules (Basel, Switzerland) · 2025Article
- Anticancer, Antioxidant and Antimicrobial Activity ofDrug design, development and therapy · 2025Article
- New Antioxidant Caffeate Esters of Fatty Alcohols Identified inMolecules (Basel, Switzerland) · 2024Article
- Phenolic Contents, Antioxidant Activities, LCMS Profiles of Mespilus germanica Leaf Extract and Effects on mRNA Transcription Levels of Apoptotic, Autophagic, and Necrotic Genes in MCF7 and A549 Cancer Cell Lines.Cell biochemistry and biophysics · 2024Article
- In Vitro and In Silico Analysis of PTP1B Inhibitors fromNutrients · 2024Article
- A redox-responsive self-assembling COA-4-arm PEG prodrug nanosystem for dual drug delivery suppresses cancer metastasis and drug resistance by downregulating hsp90 expression.Acta pharmaceutica Sinica. B · 2023Article
- Evaluation ofMetabolites · 2022Article
- Characterization and Isolation of the Major Biologically Active Metabolites Isolated fromPharmaceuticals (Basel, Switzerland) · 2022Article
- Phylogenetic Analysis ofFrontiers in plant science · 2022Article
- Chemical Constituents of the Leaves ofPlants (Basel, Switzerland) · 2021Article
- Anti-Ageing Potential ofMolecules (Basel, Switzerland) · 2021Article
- The AntioxidantAntioxidants (Basel, Switzerland) · 2021Article
- Comparative phytochemical analysis of five Egyptian strawberry cultivars (RSC advances · 2021Article
- Lupeol acetate as a potent antifungal compound against opportunistic human and phytopathogenic mold Macrophomina phaseolina.Scientific reports · 2021Article
- Chemical characterization of Saudi propolis and its antiparasitic and anticancer properties.Scientific reports · 2021Article
- Phenolic Acid Derivatives, Flavonoids and Other Bioactive Compounds from the Leaves ofPlants (Basel, Switzerland) · 2021Article
- Phytochemical Analysis and Evaluation of Biological Activity ofEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Catechol-Type Flavonoids from the Branches ofMolecules (Basel, Switzerland) · 2020Article
- Protective Evaluation of Compounds Extracted from Root ofMolecules (Basel, Switzerland) · 2020Article
- Phytotoxic Activity and Identification of Phytotoxic Substances fromPlants (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elaeagnus oldhamii Maxim. is a commonly used traditional herbal medicine. In Taiwan the leaves of E. oldhamii Maxim. are mainly used for treating lung disorders. Twenty five compounds were isolated from the leaves of E. oldhamii Maxim. in the present study. These included oleanolic acid (1), 3-O-(Z)-coumaroyl oleanolic acid (2), 3-O-(E)-coumaroyl oleanolic acid (3), 3-O-caffeoyl oleanolic acid (4), ursolic acid (5), 3-O-(Z)-coumaroyl ursolic acid (6), 3-O-(E)-coumaroyl ursolic acid (7), 3-O-caffeoyl ursolic acid (8), 3β, 13β-dihydroxyolean-11-en-28-oic acid (9), 3β, 13β-dihydroxyurs-11-en-28-oic acid (10), uvaol (11), betulin (12), lupeol (13), kaempferol (14), aromadendrin (15), epigallocatechin (16), cis-tiliroside (17), trans-tiliroside (18), isoamericanol B (19), trans-p-coumaric acid (20), protocatechuic acid (21), salicylic acid (22), trans-ferulic acid (23), syringic acid (24) and 3-O-methylgallic acid (25). Of the 25 isolated compounds, 21 compounds were identified for the first time in E. oldhamii Maxim. These included compounds 1, 4, 5 and 8-25. These 25 compounds were evaluated for their inhibitory activity against the growth of non-small cell lung cancer A549 cells by the MTT assay, and the corresponding structure-activity relationships were discussed. Among these 25 compounds, compound 6 displayed the best activity against the A549 cell line in vitro (CC50=8.56±0.57 μg/mL, at 48 h of MTT asssay). Furthermore, compound 2, 4, 8 and 18 exhibited in vitro cytotoxicity against the A549 cell line with the CC50 values of less than 20 μg/mL at 48 h of MTT asssay. These five compounds 2, 4, 6, 8 and 18 exhibited better cytotoxic activity compared with cisplatin (positive control, CC50 value of 14.87±1.94 μg/mL, at 48 h of MTT asssay). The result suggested that the five compounds might be responsible for its clinical anti-lung cancer effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.